Karyopharm Therapeutics (KPTI) Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in PFSl in Patients with Unresectable Dedifferentiated Liposarcoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Karyopharm Therapeutics (KPTI) Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in PFSl in Patients with Unresectable Dedifferentiated Liposarcoma

Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 1c

November 2, 2020 5:03 PM EST

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.73), $0.01 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $21.33 million versus the consensus estimate of $21.45 million.

"We are delighted to share the significant top-line results from the Phase 3 portion of the SEAL study, the first, late-stage clinical data for XPOVIO in a solid tumor indication," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of... More